https://www.selleckchem.com/pr....oducts/etomoxir-na-s
KT/mTOR inhibitors in advanced recurrent ovarian cancer patients is limited to a small subgroup and selection of patients with the use of current biomarkers did not improved the CBR significantly. Given the toxicity profile, we suggest that current treatment with PI3K/AKT/mTOR inhibitors should not be initiated unless in clinical trials. Furthermore, improved biomarkers to measure functional PI3K/AKT/mTOR pathway activity are needed to optimize patient selection. Lymphovascular space invasion (LVSI), deep (1/3) stromal inva
Like
Comment
Share
